Hairy cell leukaemia: Biological and clinical overview from immunogenetic insights

Hematological Oncology

Volumn 29, Issue 2, 2011, Pages 55-66

  Forconi, Francesco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Hairy cell leukaemia; Immunoglobulin genes; Pathogenesis; Prognosis

Indexed keywords

ALPHA INTERFERON; B LYMPHOCYTE RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CD20 ANTIBODY; CD20 ANTIGEN; CD23 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD44V ANTIGEN; CD63 ANTIGEN; CLADRIBINE; COLLAGEN TYPE 3; DNA; ENDOGLIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2 RECEPTOR; PENTOSTATIN; PROTEIN P53; RITUXIMAB; RNA; SYNDECAN; SYNDECAN 3; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR C MAF; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

CD25+ T LYMPHOCYTE; CLINICAL FEATURE; CLONOGENIC ASSAY; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HAIRY CELL LEUKEMIA; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOGENETICS; IMMUNOGLOBULIN GENE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CLADRIBINE; HUMANS; IMMUNOGENETIC PROCESSES; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, HAIRY CELL; MUTATION; RECEPTORS, ANTIGEN, B-CELL;

EID: 79959212916     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.975     Document Type: Review

References (135)

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958; 13(7): 609-630.
2. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th edn). WHO press, IARC: Geneva, 2008; 441.
3. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004; 363(9424): 1869-1870.
4. Forconi F, Raspadori D, Lenoci M, Lauria F. Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies. Haematologica 2005; 90(2): 266-268.
5. Kreitman RJ, Pastan I. Immunotoxins in the treatment of refractory hairy cell leukemia. Hematol Oncol Clin North Am 2006; 20(5): 1137-1151.
6. Vardiman JW, Golomb HM. Autopsy findings in hairy cell leukemia. Semin Oncol 1984; 11(4): 370-380.
7. Scheinberg M, Brenner AI, Sullivan AL, Cathcart ES, Katayama I. The heterogeneity of leukemic reticuloendotheliosis, "hairy cell leukemia". Evidence for its monocytic origin. Cancer 1976; 37(3): 1302-1307.
8. Utsinger PD, Yount WJ, Fuller CR, Logue MJ, Orringer EP. Hairy cell leukemia: B-lymphocyte and phagocytic properties. Blood 1977; 49(1): 19-27.
9. Jansen J, Meijer CJ, van der Valk P, et al. Phagocytic potential of hairy cells. Scand J Haematol 1979; 23(1): 69-79.
10. Rosner MC, Golomb HM. Phagocytic capacity of hairy cells from seventeen patients. Virchows Arch B Cell Pathol Incl Mol Pathol 1982; 40(3): 327-337.
11. Farcet JP, Gourdin MF, Testa U, Andre C, Jouault H, Reyes F. Expression of an accessory cell phenotype by hairy cells during lymphocyte colony formation in agar culture. Leuk Res 1983; 7(1): 87-95.
12. Golomb HM, Leatherman E, Rosner MC. Hairy cell leukemia: differences in phagocytic capacity of cells in vitro. Virchows Arch B Cell Pathol Incl Mol Pathol 1979; 30(1): 1-13.
13. De Panfilis G, Manara GC, Ferrari C, Torresani C, Sansoni P. Hairy cell leukemia cells express CD1a antigen. Cancer 1988; 61(1): 52-57.
14. Fu SM, Winchester RJ, Rai KR, Kunkel HG. Hairy cell leukemia: proliferation of a cell with phagocytic and B-lymphocyte properties. Scand J Immunol 1974; 3(6): 847-851.
15. Alexander E, Sanders S. Fc receptor bearing 'hairy cells' of leukaemic reticuloendotheliosis bind soluble antigen-antibody complexes and adhere to immobilized complexes, but fail to mediate antibody dependent cellular cytotoxicity. Scand J Immunol 1978; 8(6): 477-488.
16. Burns GF, Cawley JC, Worman CP, et al. Multiple heavy chain isotypes on the surface of the cells of hairy cell leukemia. Blood 1978; 52(6): 1132-1147.
17. Golomb HM, Mintz U, Vardiman J, Wilson C, Rosner MC. Surface immunoglobulin, lectin-induced cap formation, and phagocytic function in five patients with the leukemic phase of hairy cell leukemia. Cancer 1980; 46(1): 50-55.
18. Cawley JC, Burns GF, Nash TA, Higgy KE, Child JA, Roberts BE. Hairy-cell leukemia with T-cell features. Blood 1978; 51(1): 61-69.
19. Golomb HM, Davis S, Wilson C, Vardiman J. Surface immunoglobulins on hairy cells of 55 patients with hairy cell leukemia. Am J Hematol 1982; 12(4): 397-401.
20. Worman CP, Beverley PC, Cawley JC. Alterations in the phenotype of hairy cells during culture in the presence of PHA: requirement for T cells. Blood 1982; 59(5): 895-899.
21. Forconi F, Sahota SS, Raspadori D, Mockridge CI, Lauria F, Stevenson FK. Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood 2001; 98(4): 1174-1181.
22. Korsmeyer SJ, Greene WC, Cossman J, et al. Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci USA 1983; 80(14): 4522-4526.
23. Anderson KC, Boyd AW, Fisher DC, Leslie D, Schlossman SF, Nadler LM. Hairy cell leukemia: a tumor of pre-plasma cells. Blood 1985; 65(3): 620-629.
24. Basso K, Liso A, Tiacci E, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 2004; 199(1): 59-68.
25. Vanhentenrijk V, Tierens A, Wlodarska I, Verhoef G, Wolf-Peeters CD. V(H) gene analysis of hairy cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin. Leukemia 2004; 18(10): 1729-1732.
26. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194(11): 1625-1638.
27. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998; 188(9): 1679-1689.
28. Marafioti T, Jones M, Facchetti F, et al. Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology. Blood 2003; 102(8): 2868-2876.
29. Weston-Bell N, Townsend M, Di Genova G, Forconi F, Sahota SS. Defining origins of malignant B cells: a new circulating normal human IgM(+)D(+) B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population. Leukemia 2009.
30. Li J, Barreda DR, Zhang YA, et al. B lymphocytes from early vertebrates have potent phagocytic and microbicidal abilities. Nat Immunol 2006; 7(10): 1116-1124.
31. Guglielmi P, Preud'homme JL, Flandrin G. Phenotypic changes of phytohaemagglutinin-stimulated hairy cells. Nature 1980; 286(5769): 166-168.
32. Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer 2006; 6(6): 437-448.
33. Cawley JC, Hawkins SF. The biology of hairy-cell leukaemia. Curr Opin Hematol 2010; 17(4): 341-349.
34. Foa R, Guarini A, Francia diCelle P., et al. Constitutive production of tumor necrosis factor-alpha in hairy cell leukemia: possible role in the pathogenesis of the cytopenia(s) and effect of treatment with interferon-alpha. J Clin Oncol 1992; 10(6): 954-959.
35. Aziz KA, Till KJ, Chen H, et al. The role of autocrine FGF-2 in the distinctive bone marrow fibrosis of hairy-cell leukemia (HCL). Blood 2003; 102(3): 1051-1056.
36. Cawley JC. The pathophysiology of the hairy cell. Hematol Oncol Clin North Am 2006; 20(5): 1011-1021.
37. Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Duechler M, Gisslinger H. TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest 2004; 113(5): 676-685.
38. Forconi F, Poretti G, Kwee I, et al. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. Br J Haematol 2008; 141(5): 622-630.
39. Guasch G, Delaval B, Arnoulet C, et al. FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice. Blood 2004; 103(1): 309-312.
40. Pole JC, Courtay-Cahen C, Garcia MJ, et al. High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. Oncogene 2006; 25(41): 5693-5706.
41. Lupski JR, Stankiewicz P. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet 2005; 1(6): e49.
42. Ruco LP, Procopio A, Maccallini V, et al. Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. Blood 1983; 61(6): 1132-1137.
43. Jansen JH, van der Harst D, Wientjens GJ, et al. Induction of CD11a/leukocyte function antigen-1 and CD54/intercellular adhesion molecule-1 on hairy cell leukemia cells is accompanied by enhanced susceptibility to T-cell but not lymphokine-activated killer-cell cytotoxicity. Blood 1992; 80(2): 478-483.
44. van der Horst FA, van der Marel A, den Ottolander GJ, Kluin-Nelemans HC. Decrease of memory T helper cells (CD4+ CD45R0+) in hairy cell leukemia. Leukemia 1993; 7(1): 46-50.
45. Kluin-Nelemans JC, Kester MG, Oving I, Cluitmans FH, Willemze R, Falkenburg JH. Abnormally activated T lymphocytes in the spleen of patients with hairy-cell leukemia. Leukemia 1994; 8(12): 2095-2101.
46. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984; 310(1): 15-18.
47. Kluin-Nelemans HC, Jansen JH. Residual T lymphocytes, and not malignant B cells, proliferate upon mitogenic stimulation. Leukemia 1989; 3(10): 715-717.
48. Kluin-Nelemans JC, Kester MG, Melenhorst JJ, et al. Persistent clonal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia. Blood 1996; 87(9): 3795-3802.
49. Arons E, Sorbara L, Raffeld M, et al. Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. Cancer Immunol Immunother 2006; 55(9): 1100-1110.
50. Kluin-Nelemans HC, Kester MG, van deCorput L, et al. Correction of abnormal T-cell receptor repertoire during interferon-alpha therapy in patients with hairy cell leukemia. Blood 1998; 91(11): 4224-4231.
51. Lund FE, Randall TD. Effector regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010; 10(4): 236-247.
52. Rajewsky K, von Boehmer H. Lymphocyte development: overview. Curr Opin Immunol 2008; 20(2): 127-130.
53. Uckun FM. Regulation of human B-cell ontogeny. Blood 1990; 76(10): 1908-1923.
54. Berek C. The development of B cells and the B-cell repertoire in the microenvironment of the germinal center. Immunol Rev 1992; 126: 5-19.
55. Stevenson FK, Sahota SS, Ottensmeier CH, Zhu D, Forconi F, Hamblin TJ. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res 2001; 83: 81-116.
56. Honjo T, Kinoshita K, Muramatsu M. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu Rev Immunol 2002; 20: 165-196.
57. Han S, Zheng B, Schatz DG, Spanopoulou E, Kelsoe G. Neoteny in lymphocytes: Rag1 and Rag2 expression in germinal center B cells. Science 1996; 274(5295): 2094-2097.
58. Giachino C, Padovan E, Lanzavecchia A. Re-expression of RAG-1 and RAG-2 genes and evidence for secondary rearrangements in human germinal center B lymphocytes. Eur J Immunol 1998; 28(11): 3506-3513.
59. Goossens T, Brauninger A, Klein U, Kuppers R, Rajewsky K. Receptor revision plays no major role in shaping the receptor repertoire of human memory B cells after the onset of somatic hypermutation. Eur J Immunol 2001; 31(12): 3638-3648.
60. MacLennan IC, Toellner KM, Cunningham AF, et al. Extrafollicular antibody responses. Immunol Rev 2003; 194: 8-18.
61. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK, Unmutated Ig. V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94(6): 1848-1854.
62. Kienle D, Krober A, Katzenberger T, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003; 102(8): 3003-3009.
63. Kitchingman GR, Mirro J, Stass S, et al. Biologic and prognostic significance of the presence of more than two mu heavy-chain genes in childhood acute lymphoblastic leukemia of B precursor cell origin. Blood 1986; 67(3): 698-703.
64. Sahota SS, Forconi F, Ottensmeier CH, et al. Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002; 100(4): 1505-1507.
65. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94(6): 1840-1847.
66. Forconi F, Sahota SS, Raspadori D, et al. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood 2004; 104(10): 3312-3317.
67. Kipps TJ, Tomhave E, Pratt LF, Duffy S, Chen PP, Carson DA. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1989; 86(15): 5913-5917.
68. Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 1997; 158(1): 235-246.
69. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008; 111(3): 1524-1533.
70. Widhopf GF 2nd, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004; 104(8): 2499-2504.
71. Widhopf GF 2nd, Goldberg CJ, Toy TL, et al. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood 2008; 111(6): 3137-3144.
72. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004; 200(4): 519-525.
73. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007; 109(1): 259-270.
74. Forconi F, Potter KN, Wheatley I, et al. The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood 2010; 115(1): 71-77.
75. Maloum K, Magnac C, Azgui Z, et al. VH gene expression in hairy cell leukaemia. Br J Haematol 1998; 101(1): 171-178.
76. Arons E, Sunshine J, Suntum T, Kreitman RJ. Somatic hypermutation and VH gene usage in hairy cell leukaemia. Br J Haematol 2006; 133(5): 504-512.
77. Forconi F, Sozzi E, Rossi D, et al. Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. Haematologica 2008; 93(5): 697-705.
78. Thorselius M, Walsh SH, Thunberg U, Hagberg H, Sundstrom C, Rosenquist R. Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia. Leuk Res 2005; 29(2): 153-158.
79. Forconi F, Sozzi E, Cencini E, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009; 114(21): 4696-4702.
80. Kayano H, Dyer MJ, Zani VJ, et al. Aberrant rearrangements within the immunoglobulin heavy chain locus in hairy cell leukemia. Leuk Lymphoma 1994; 14 (Suppl 1): 41-47.
81. Kluin-Nelemans HC, Krouwels MM, Jansen JH, et al. Hairy cell leukemia preferentially expresses the IgG3-subclass. Blood 1990; 75(4): 972-975.
82. Haak HL, de Man JC, Hijmans W, Speck B. Further evidence for the lymphocytic nature of leukaemic reticuloendotheliosis (hairy-cell leukaemia). Br J Haematol 1974; 27(1): 31-38.
83. Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 1993; 82(4): 1277-1287.
84. Heirman C, Vaeremans E, Carels D, Theunissen J, Van Camp B, Thielemans K. Isotype switch and idiotype variation in hairy cell leukemia. Leukemia 1990; 4(12): 856-862.
85. Ramiro AR, Stavropoulos P, Jankovic M, Nussenzweig MC. Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand. Nat Immunol 2003; 4(5): 452-456.
86. Muto T, Muramatsu M, Taniwaki M, Kinoshita K, Honjo T. Isolation tissue distribution, and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene. Genomics 2000; 68(1): 85-88.
87. Greeve J, Philipsen A, Krause K, et al. Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. Blood 2003; 101(9): 3574-3580.
88. Smit LA, Bende RJ, Aten J, Guikema JE, Aarts WM, van Noesel CJ. Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype. Cancer Res 2003; 63(14): 3894-3898.
89. Fujieda S, Lin YQ, Saxon A, Zhang K. Multiple types of chimeric germ-line Ig heavy chain transcripts in human B cells: evidence for trans-splicing of human Ig RNA. J Immunol 1996; 157(8): 3450-3459.
90. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010; 465(7301): 1033-1038.
91. Sozzi E, Amato T, Sahota SS, et al. Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia. Hematol Oncol 2010.
92. Mizuta TR, Suzuki N, Shimizu A, Honjo T. Duplicated variable region genes account for double isotype expression in a human leukemic B-cell line that gives rise to single isotype-expressing cells. J Biol Chem 1991; 266(19): 12514-12521.
93. Oppezzo P, Magnac C, Bianchi S, et al. Do CLL B cells correspond to naive or memory B-lymphocytes? Evidence for an active Ig switch unrelated to phenotype expression and Ig mutational pattern in B-CLL cells. Leukemia 2002; 16(12): 2438-2446.
94. Lauria F, Forconi F. Towards the pharmacotherapy of hairy cell leukaemia. Expert Opin Pharmacother 2004; 5(7): 1523-1533.
95. Baker PK, Pettitt AR, Slupsky JR, et al. Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood 2002; 100(2): 647-653.
96. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995; 13(4): 974-982.
97. Spiers AS, Parekh SJ. Complete remission in hairy cell leukaemia achieved with pentostatin. Lancet 1984; 1(8385): 1080-1081.
98. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322(16): 1117-1121.
99. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92(6): 1918-1926.
100. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145(6): 733-740.
101. Tallman MS, Hakimian D, Rademaker AW, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 1996; 88(6): 1954-1959.
102. Dalal BI, Freier L, Johnston JB, Merry CC, Israels LG. Peripheral blood and bone marrow changes following 2'-deoxycoformycin therapy in hairy cell leukemia. Results of 200 weeks' follow-up. Cancer 1989; 63(1): 14-22.
103. Kraut EH, Neff JC, Bouroncle BA, Gochnour D, Grever MR. Immunosuppressive effects of pentostatin. J Clin Oncol 1990; 8(5): 848-855.
104. Raspadori D, Rondelli D, Birtolo S, et al. Long-lasting decrease of CD4+/CD45RA+ T cells in HCL patients after 2-chlorodeoxyadenosine (2-CdA) treatment. Leukemia 1999; 13(8): 1254-1257.
105. Hagberg H, Lundholm L. Rituximab a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001; 115(3): 609-611.
106. Lauria F, Lenoci M, Annino L, et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001; 86(10): 1046-1050.
107. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006; 107(12): 4658-4662.
108. Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102(12): 3906-3911.
109. Forconi F, Toraldo F, Sozzi E, Amato T, Raspadori D, Lauria F. Complete molecular remission induced by concomitant cladribine-rituximab treatment in a case of multi-resistant hairy cell leukemia. Leuk Lymphoma 2007; 48(12): 2441-2443.
110. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006; 8(3): E532-E551.
111. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23(27): 6719-6729.
112. Piro LD, Ellison DJ, Saven A. The scripps clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994; 14 (Suppl 1): 121-125.
113. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21(5): 891-896.
114. Kreitman RJ. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr Pharm Des 2009; 15(23): 2652-2664.
115. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009; 27(18): 2983-2990.
116. Lauria F, Forconi F. Combination therapies to improve the long-term outcome in hairy cell leukemia. Leuk Lymphoma 2009; 50 (Suppl 1): 18-22.
117. Dearden C, Else M. Hairy cell leukemia. Curr Oncol Rep 2006; 8(5): 337-342.
118. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994; 83(12): 3672-3681.
119. Saven A. Piro LD: 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994; 120(9): 784-791.
120. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003; 102(3): 810-813.
121. Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 2004; 89(3): 309-313.
122. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005; 104(11): 2442-2448.
123. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111(12): 5446-5456.
124. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004; 103(12): 4389-4395.
125. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343(26): 1910-1916.
126. Pettitt AR, Sherrington PD, Cawley JC. The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. Br J Haematol 1999; 106(4): 1049-1051.
127. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74(6): 957-967.
128. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112(8): 3322-3329.
129. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009; 15(3): 995-1004.
130. Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101(12): 4975-4981.
131. Vasconcelos Y, Davi F, Levy V, et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol 2003; 21(21): 3928-3932.
132. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100(4): 1410-1416.
133. Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009; 114(21): 4687-4695.
134. Kreitman RJ, Pastan I. BL22 and lymphoid malignancies. Best Pract Res Clin Haematol 2006; 19(4): 685-699.
135. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007; 110(10): 2240-2247.